Gain Therapeutics Shares Owned By Insiders vs. Current Valuation

GANX Stock  USD 1.84  0.25  15.72%   
Based on Gain Therapeutics' profitability indicators, Gain Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Gain Therapeutics' ability to earn profits and add value for shareholders. At this time, Gain Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 205.28 in 2024, whereas Price To Sales Ratio is likely to drop 732.51 in 2024. At this time, Gain Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Net Interest Income is likely to rise to about 579.3 K in 2024, despite the fact that Operating Income is likely to grow to (21.1 M).
For Gain Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Gain Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Gain Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Gain Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Gain Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.24)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(1.89)
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Gain Therapeutics Current Valuation vs. Shares Owned By Insiders Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Gain Therapeutics's current stock value. Our valuation model uses many indicators to compare Gain Therapeutics value to that of its competitors to determine the firm's financial worth.
Gain Therapeutics is rated below average in shares owned by insiders category among its peers. It is rated # 4 in current valuation category among its peers reporting about  7,372,498  of Current Valuation per Shares Owned By Insiders. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gain Therapeutics' earnings, one of the primary drivers of an investment's value.

Gain Current Valuation vs. Shares Owned By Insiders

Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Gain Therapeutics

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
5.09 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Gain Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
37.53 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Gain Current Valuation vs Competition

Gain Therapeutics is rated # 4 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 329.32 Million. Gain Therapeutics retains roughly 37.53 Million in current valuation claiming about 11% of equities under Health Care industry.

Gain Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Gain Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Gain Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Gain Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Gain Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income247.2 K259.6 K
Net Interest Income551.7 K579.3 K
Operating Income-22.3 M-21.1 M
Net Loss-22.2 M-21.1 M
Income Before Tax-22.2 M-21.1 M
Total Other Income Expense Net64.9 K68.1 K
Net Loss-15.8 M-15 M
Net Loss-22.3 M-21.2 M
Income Tax Expense79.3 K83.2 K
Interest Income494.2 K478.3 K
Non Operating Income Net Other-86.5 K-90.8 K
Change To Netincome1.5 M1.6 M
Net Loss(1.71)(1.80)
Income Quality 0.85  0.66 
Net Income Per E B T 1.00  1.10 

Gain Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Gain Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Gain Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Gain Therapeutics' important profitability drivers and their relationship over time.

Use Gain Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Gain Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gain Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Gain Therapeutics Pair Trading

Gain Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Gain Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Gain Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Gain Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Gain Therapeutics to buy it.
The correlation of Gain Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Gain Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Gain Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Gain Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Gain Therapeutics position

In addition to having Gain Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Volatility ETFs Thematic Idea Now

Volatility ETFs
Volatility ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.